Rvx.To
RVX.TO operates in the biotechnology and medical research sector, focusing on pharmaceuticals and medical research.
Business. RVX.TO operates in the biotechnology and medical research sector, focusing on pharmaceuticals and medical research.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
RVX.TO operates in the biotechnology and medical research sector, focusing on pharmaceuticals and medical research.
RVX.TO's capital structure is characterized by a significant debt burden, with total liabilities of $96.91 million and total equity of -$88.96 million, resulting in a debt-to-equity ratio of -0.69. The company's liquidity position is weak, as indicated by a current ratio of 0.04, suggesting a high risk of short-term financial distress. The negative net income of $7.77 million and operating income of $5.06 million further underscore the company's financial instability.
In terms of profitability, RVX.TO's return on equity is 8.73%, which is relatively high given the company's negative equity position. However, the return on assets is -9.77%, indicating that the company is not effectively utilizing its assets to generate profit. These metrics are below the industry norms for biotechnology firms, which typically require strong R&D investment and high returns to justify their operations.
RVX.TO's revenue concentration is not explicitly detailed in the provided data, but the company's financial snapshot suggests a lack of diversification in its revenue streams. The negative net income and operating income indicate that the company may be heavily reliant on a few key products or services, which could pose a significant risk if those areas underperform.
The growth trajectory of RVX.TO is concerning, with the company reporting negative operating and net income. The lack of positive financial performance suggests that the company may be struggling to scale its operations or achieve profitability. The capital expenditure of $696,000 indicates some level of investment in the business, but it is not sufficient to offset the negative cash flows.
The risk assessment for RVX.TO highlights a medium liquidity risk and a low dilution risk. The company's negative net cash position after subtracting total debt is a key flag, indicating potential difficulties in meeting short-term obligations. The low dilution risk suggests that the company is not likely to issue additional shares in the near term, which could help maintain shareholder value.
Recent events and filings for RVX.TO are not detailed in the provided data, but the company's financial performance and risk profile suggest that it may be facing significant challenges. The negative financial metrics and high debt levels indicate that the company may need to take corrective actions to improve its financial health.
- RVX.TO has a high debt-to-equity ratio of -0.69, indicating a significant reliance on debt financing.
- The company's return on equity is 8.73%, which is relatively high given its negative equity position.
- RVX.TO's liquidity position is weak, with a current ratio of 0.04.
- The company's negative net income and operating income suggest financial instability.
- The risk assessment indicates a medium liquidity risk and a low dilution risk.
- **margin_outlook_rationale**: The company's negative net income and operating income suggest a decline in profitability, driven by high operating costs and low revenue.
- **rd_outlook_rationale**: The company's R&D outlook is uncertain due to the lack of detailed information on R&D expenditures and the negative financial performance.
Bull / Bear case
analysis pipelineIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- Return On Assetsnet_income / total_assets
- RVX.TO Market data — financials · 2026-05-29